-
Mashup Score: 5Targeted TLR9 Agonist Elicits Effective Antitumor Immunity against Spontaneously Arising Breast Tumors - 9 month(s) ago
Key Points. PIP-CpG is a systemically administered, tumor-targeting TLR9 agonist.PIP-CpG drives effective T cell–mediated immunity against spontaneous breast tu
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 6Please wait whilst we redirect you - 12 month(s) ago
About ScienceDirectRemote accessShopping cartAdvertiseContact and supportTerms and conditionsPrivacy policyWe use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.Copyright © 2023 Elsevier B.V. or its licensors or contributors. ScienceDirect® is a registered trademark of Elsevier B.V.ScienceDirect® is a registered trademark…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Key Points. Androgen deprivation therapy results in increased recent thymic emigrants (RTEs).RTEs traffic to prostate tumors.RTEs become activated and produce e
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 0
Vγ9Vδ2+ T cell–targeted immunotherapy is of interest to harness its MHC-independent cytotoxic potential against a variety of cancers. Recent studies have identified heterodimeric butyrophilin (BTN) 2A1 and BTN3A1 as the molecular entity providing “signal 1” to the Vγ9Vδ2 TCR, but “signal
Source: The Journal of ImmunologyCategories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 2Combination of NKG2A and PD-1 Blockade Improves Radiotherapy Response in Radioresistant Tumors - 2 year(s) ago
Radiotherapy (RT) is commonly employed to treat solid tumors. Immune checkpoint blockade of programmed cell death protein 1 (PD-1) and CTLA-4 improves survival in RT patients, yet many fail to respond to combination therapy. Natural killer group 2 (NKG2) family receptors, particularly inhibitory
Source: The Journal of ImmunologyCategories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 3LIGHT (TNFSF14) Costimulation Enhances Myeloid Cell Activation and Antitumor Immunity in the Setting of PD-1/PD-L1 and TIGIT Checkpoint Blockade - 2 year(s) ago
This article is featured in Top Reads , p.[][1] [1]: /lookup/volpage/209/429
Source: The Journal of ImmunologyCategories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 0Nature Cancer - The expanding palette of immunotherapy - 2 year(s) ago
In this issue, we launch a Series on Cancer Immunotherapy presenting commissioned Reviews and opinion pieces on the latest advances and challenges in the…
Source: NatureCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1CXCL13 as a Novel Immune Checkpoint for Regulatory B Cells and Its Role in Tumor Metastasis - 2 year(s) ago
Tumor metastasis is the primary cause of mortality in patients with cancer. Several chemokines are identified as important mediators of tumor growth and/or metastasis. The level of CXCL13 has been reported to be elevated in serum or tumor tissues in patients, which mainly functions to attract B
Source: The Journal of ImmunologyCategories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 11
Inhibitory receptors have a critical role in the regulation of immunity. Siglecs are a family of primarily inhibitory receptors expressed by immune cells that recognize specific sialic acid modifications on cell surface glycans. Many tumors have increased sialic acid incorporation. Overexpression of
Source: The Journal of ImmunologyCategories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 8Combinatorial Expression of NK Cell Receptors Governs Cell Subset Reactivity and Effector Functions but Not Tumor Specificity - 2 year(s) ago
This article is featured in Top Reads , p.[][1] [1]: /lookup/volpage/208/1515
Source: The Journal of ImmunologyCategories: Allergy-Immunology, Latest HeadlinesTweet
#JI_TopRead from @CaitlynBioE @CochranLab @CarolynBertozzi @StanfordHealth | #TLR9 agonist, PIP-CpG, enhances the CD8 #Tcell response to spontaneous tumors | #ReadTheJI #immunology #AuthorChoice #FreetoRead #TumorImmunology 👉 https://t.co/KdOxutKuLh https://t.co/rb99fBIOLb